Literature DB >> 15467899

Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke.

Christine Duering1, Andrea Kosch, Claus Langer, Sabine Thedieck, Ulrike Nowak-Göttl.   

Abstract

Tissue factor pathway inhibitor (TFPI) plays an important role in inhibiting tissue factor-induced coagulation by a factor Xadependent pathway of the activated tissue-factor VIIa complex. Decreased values of the latter inhibitor have been recently reported in adult patients with venous thrombosis (VT) or ischaemic stroke (IS). The present case-control study was therefore performed to evaluate whether a decreased TFPI concentration is also involved in paediatric symptomatic thromboembolism (ST). Total TFPI concentrations were measured along with established prothrombotic risk factors six to twelve months after the acute thrombotic onset in 144 Caucasian children aged 0.6 to 18 years (VT: n=80; IS: n=64). The cut-off values defined as age-dependent 10(th) percentiles were obtained from 244 healthy controls. Median (range) values of TFPI were significantly lower in patients compared with control subjects [50.0(20.0-132.3) ng/ml vs. 59.5(25.4-117.4) ng/ml; p-value < 0.0001]. In addition, 42 of the 144 patients (29.2%) compared with 25 of the 244 controls (10.2%) showed TFPI concentrations below the 10(th) age-dependent percentiles. Compared to baseline values 78.6% of children with total TFPI Ag < 10(th) percentiles showed a low response to enoxaparin administration, whereas in children with normal baseline TFPI values 30% show a low TFPI release (p = 0.007). Multivariate analysis adjusted for the presence of established prothrombotic risk factors showed a significantly increased odds ratio (OR) and 95% confidence interval (CI) for patients with ST [OR/CI: 3.8/2.2-6.6; p < 0.0001]. Data shown here give evidence that total TFPI concentrations below the 10(th) age-dependent percentiles independently increase the risk of ST in Caucasian children 3.8-fold.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15467899     DOI: 10.1160/TH04-05-0293

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays.

Authors:  Raj S Kasthuri; Sam L Glover; Jeremiah Boles; Nigel Mackman
Journal:  Semin Thromb Hemost       Date:  2010-10-26       Impact factor: 4.180

2.  Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy.

Authors:  Jacques E Rossouw; Karen C Johnson; Mary Pettinger; Mary Cushman; Per Morten Sandset; Lewis Kuller; Frits Rosendaal; Jan Rosing; Sylvia Wasserthal-Smoller; Lisa W Martin; Joann E Manson; Kamakshi Lakshminarayan; Jose G Merino; John Lynch
Journal:  Stroke       Date:  2012-02-23       Impact factor: 7.914

3.  Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology.

Authors:  Neil A Zakai; Pamela L Lutsey; Aaron R Folsom; Susan R Heckbert; Mary Cushman
Journal:  Thromb Haemost       Date:  2010-04-29       Impact factor: 5.249

4.  Novel protein ADTRP regulates TFPI expression and function in human endothelial cells in normal conditions and in response to androgen.

Authors:  Cristina Lupu; Hua Zhu; Narcis I Popescu; Jonathan D Wren; Florea Lupu
Journal:  Blood       Date:  2011-08-25       Impact factor: 22.113

Review 5.  Expression of tissue factor pathway inhibitor by endothelial cells and platelets.

Authors:  Susan A Maroney; Alan E Mast
Journal:  Transfus Apher Sci       Date:  2008-02-07       Impact factor: 1.764

6.  Genetics of hemostasis: differential effects of heritability and household components influencing lipid concentrations and clotting factor levels in 282 pediatric stroke families.

Authors:  Ulrike Nowak-Göttl; Claus Langer; Sandra Bergs; Sabine Thedieck; Ronald Sträter; Monika Stoll
Journal:  Environ Health Perspect       Date:  2008-06       Impact factor: 9.031

7.  Combined tissue factor pathway inhibitor and thrombomodulin deficiency produces an augmented hypercoagulable state with tissue-specific fibrin deposition.

Authors:  S A Maroney; B C Cooley; R Sood; H Weiler; A E Mast
Journal:  J Thromb Haemost       Date:  2007-10-25       Impact factor: 5.824

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.